Submit your email to push it up the queue
BARD Peripheral Vascular, Inc., a subsidiary of C. R. Bard, Inc., is a leading player in the medical device industry, specialising in innovative solutions for vascular access and peripheral vascular interventions. Headquartered in the United States, the company operates extensively across North America and Europe, providing critical products that enhance patient care. Founded in the early 1960s, BARD Peripheral Vascular has achieved significant milestones, including the development of advanced catheter technologies and vascular grafts. Their core offerings, such as the innovative AngioJet® Thrombectomy System and various stent systems, are distinguished by their efficacy and reliability in treating vascular diseases. With a strong market position, BARD Peripheral Vascular is recognised for its commitment to quality and innovation, making it a trusted name among healthcare professionals and patients alike.
How does BARD Peripheral Vascular, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
BARD Peripheral Vascular, Inc.'s score of 67 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
BARD Peripheral Vascular, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Becton, Dickinson and Company, which may influence its climate commitments and emissions reporting. As part of its corporate family relationship, BARD Peripheral Vascular inherits emissions data and climate initiatives from Becton, Dickinson and Company. This includes participation in various climate initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are cascaded from Becton, Dickinson and Company. However, specific reduction targets or achievements for BARD Peripheral Vascular have not been disclosed. While no absolute emissions figures are provided, the company is expected to align with the sustainability goals and climate strategies of its parent organisation, which may include commitments to reduce emissions across Scope 1, 2, and 3 categories. As such, BARD Peripheral Vascular is positioned within a broader context of corporate responsibility and climate action, although specific metrics and targets remain unspecified.
Access structured emissions data, company-specific emission factors, and source documents
2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 96,333,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 514,801,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | 158,622,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
BARD Peripheral Vascular, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.